ALFA Finder| Revenue growth | 21% Q4 growth; full year up 17% surpassing ₹5,000cr. |
|---|---|
| Margins | EBITDA margin at 26% FY26; guiding for 27% in FY27. |
| Demand visibility | Strong domestic and US outlook; cautious on Middle East logistics. |
| Management confidence | High, despite logistical headwinds in Asia and Africa. |
Growth
Revenue grew 21% in Q4 and 17% for FY26; US generics led with 49% annual growth.
Outlook
FY27 guidance: revenue growth in 'high teens', EBITDA margin targeted at 27%, and capex of ₹400cr.
Risks
Asia business declined 10% in Q4 due to Red Sea logistical disruptions; rising freight and R&D costs.
Earnings Call filed with BSE, NSE: AJANTPHARM. Summary written with AI assistance from the document.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,319.60
- Market cap
- ₹41,481 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 32.9×Sector 43.8×
- Promoter holding
- 63.47%-0.01% QoQ
- FII holding
- 7.62%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma posted robust revenue and PAT growth, primarily driven by a temporary US market upside. Management remains cautious as competition intensifies.
- Call
- Guides 18% growth
Ajanta Pharma Q2 FY27 Results: Net Profit ₹388.1 Cr, Up 49.2% YoY
Ajanta Pharma Ltd reported revenue from operations of ₹1,794 Cr (+32.5% YoY) and net profit of ₹388.1 Cr (+49.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹388.1 Cr · +49.2% YoY
Ajanta Pharma Share Pledge
Ajanta Pharma promoter Aayush Agrawal (trustee) created a pledge on 30,000 equity shares. The pledge was made as a top-up call due to share price reduction.
Ajanta Pharma Board Meeting Date
Ajanta Pharma has scheduled a Board meeting for 30 October 2026 to consider Q2/H1 2026 unaudited financial results. No material decision has been taken yet.
Ajanta Pharma Other Announcement
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust created pledge on 4,60,000 Ajanta Pharma shares. The pledge secures an NCD issue in favor of CTL Trusteeship Ltd.